May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Interleukin-6 Combined with Soluble Interleukin-6 Receptor Inhibits Neuronal Cell Death by NMDA in Rat Retinas
A. Hirata; Y. Inomata; N. Yonemura; T. Koga; N. Kido; H. Tanihara
Author Affiliations & Notes
  • A. Hirata
    Dept of Ophthalmology, Kumamoto Univ Sch of Medicine, Kumamoto, Japan
  • Y. Inomata
    Dept of Ophthalmology, Kumamoto Univ Sch of Medicine, Kumamoto, Japan
  • N. Yonemura
    Dept of Ophthalmology, Kumamoto Univ Sch of Medicine, Kumamoto, Japan
  • T. Koga
    Dept of Ophthalmology, Kumamoto Univ Sch of Medicine, Kumamoto, Japan
  • N. Kido
    Dept of Ophthalmology and Visual Sciences, Kyoto University Graduate School, Kyoto, Japan
  • H. Tanihara
    Dept of Ophthalmology and Visual Sciences, Kyoto University Graduate School, Kyoto, Japan
  • Footnotes
    Commercial Relationships  A. Hirata, None; Y. Inomata, None; N. Yonemura, None; T. Koga, None; N. Kido, None; H. Tanihara, None.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 5207. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Interleukin-6 Combined with Soluble Interleukin-6 Receptor Inhibits Neuronal Cell Death by NMDA in Rat Retinas
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      A. Hirata, Y. Inomata, N. Yonemura, T. Koga, N. Kido, H. Tanihara; Interleukin-6 Combined with Soluble Interleukin-6 Receptor Inhibits Neuronal Cell Death by NMDA in Rat Retinas . Invest. Ophthalmol. Vis. Sci. 2003;44(13):5207.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Abstract: : Purpose: To determine if interleukin-6 (IL-6) combined with soluble Interleukin-6 receptor (sIL-6R) modulates N-methyl-D-aspartate (NMDA)-induced retinal damage. Methods:Eyes of Sprague-Dawley rats pretreated with a combined injection IL-6 (5 to 500 ng/eye) and sIL-6R (2.5 to 250 ng/eye) was administered with NMDA (20 nmol) into the vitreous cavity. PBS were injected as control. Each eye was enucleated and transverse sections were subjected to morphometric analysis. The degree of NMDA-induced retinal neuronal death was quantified by cell counts in the ganglion cell layer (GCL) and by the thickness of the inner plexiform layer (IPL). Retrograde labeling with a fluorescent tracer (fluoro-Gold) was applied for counting survival retinal ganglion cells (RGCs). Apoptotic changes in the retina were assessed by the TUNEL method. Western blotting analysis was perfomed for examination of gp130 in NMDA injected retina. Results:Treatment with IL-6 only, or sIL-6R did not bring neuroprotective effects against NMDA-induced retinal damage. However, pretreatment with IL-6 (5-500ng) combined with sIL-6R (2.5-250ng) induced significant neuroprotective effects on NMDA-induced retinal damage. The differences between the numbers for the GCLs and the thickness of the IPL in PBS- and combined IL-6 with sIL-6R-injected eyes were statistically significant.(p<0.05, p<0.005). In analysis of retrograde labeling of RGCs, at 7 days after NMDA was injected into the eyes, the mean densities for the RGCs of control (PBS-injected) and experimental (50 ng IL-6 and 25 ng sIL-6R, 5 ng IL-6 and 2.5 ng sIL-6R-pretreated) were statistically significant.(p<0.005, p<0.005). In TUNEL method, pretreatment with IL-6 combined with sIL-6R prevents NMDA induced apoptosis. Western blotting studies demonstrated upregulation of gp130 expression in NMDA-injected retina. Conclusions:Present studies suggest that IL-6 combined with sIL-6R provides neuroprotective effects on NMDA-induced retinal damage.

Keywords: cytokines/chemokines • neuroprotection • retina: proximal(bipolar, amacrine, and gangli 
© 2003, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept